TLSA•benzinga•
Tiziana Life Sciences Announced Findings On Benefits Of Its Nasal Anti-CD3 Monoclonal Antibody In Sustaining Tissue Homeostasis And Mitigating The Side Effects Associated With GLP-1 Agonists Discontinuation
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga